Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by Rusty2018on Jan 03, 2021 12:09pm
190 Views
Post# 32211531

RE:RE:RE:Ok, let's ask ourselves a question?

RE:RE:RE:Ok, let's ask ourselves a question?Lets look at it another way.
say there are a few companies (candidates) that have a vaccine readily available to deploy to the poor countries around the world.
Population to be inncoulated - around 3 Billion for arguments sake.
Let's pick a number for cost of vaccine - or another approach maybe - say $1 flows to a companies top line before expenses - royalty, or if companies manufacture on thier own - whatever.
Let's say there are 4 companies then...another argument statement but let's get some dialouge.
so 3Billion x $1 is $3Billion. 2 doses perhaps ($6billion) divided by 4 compaines so 25% marketshare each...(argumentative point of course)
$2 Billion
What if like the flu there is a need to innoculate annually?
Hmmmm
Let the dialogue begin
GLTA
 
<< Previous
Bullboard Posts
Next >>